-
Categories
-
Pharmaceutical Intermediates
-
Active Pharmaceutical Ingredients
-
Food Additives
- Industrial Coatings
- Agrochemicals
- Dyes and Pigments
- Surfactant
- Flavors and Fragrances
- Chemical Reagents
- Catalyst and Auxiliary
- Natural Products
- Inorganic Chemistry
-
Organic Chemistry
-
Biochemical Engineering
- Analytical Chemistry
-
Cosmetic Ingredient
- Water Treatment Chemical
-
Pharmaceutical Intermediates
Promotion
ECHEMI Mall
Wholesale
Weekly Price
Exhibition
News
-
Trade Service
The National Institute for Health and Care Excellence (NICE) recommends combining Roche's antibody drug polyvy (polatuzumab vedotin) with rituximab and bendamustine to treat diffuse large B-cell lymphoma (DLBCL).
CD79b is a component of B-cell antigen receptors, has a high specificity, has become a new target for the treatment of B-cell lymphoma after CD20.
: According to NICE, there are about 4,800 DBCL patients in the UK, of whom about 530 are eligible for Polivy combined treatment.
, the drug combination will be available to patients with relapses or non-responsiveness after first-line treatment and who are not suitable for stem cell transplants.
in clinical trials in DLBCL patients, Polivy had a 40 percent full remission rate with Rituxan/Benzamostin, compared with 18 percent in the control group.
, the total survival of patients increased from 4.7 months to 11.8 months.
new treatment is good news for patients and clinicians, given the poor prognostic prognosticity of relapsed or resuscable DLBCL.
's drug combination was the first to show overall survival advantage in this class of patients.
.